Several studies using various tumor models have proven that TTFields can extend survival by inhibiting tumor metastatic spread, seeding, and growth by preventing angiogenesis and downregulating the expression of epithelial–mesenchymal transition-associated proteins, including actin, vimentin, and cadherin [12,59,60]. The gene discussed is CDH17; the disease is neoplasm.